[Population pharmacokinetics/pharmacodynamics of magnesium sulfate in pregnancy induced hypertensive gravidas treated with the drug].
NONMEM program was applied for analyzing population pharmacokinetics/pharmacodynamics of magnesium sulfate in pregnancy induced hypertensive patients treated with the drug. A 2-compartment open model with fast and slow consecutive intravenous infusion was used to estimate population pharmacokinetics from 60 patients. A 3-compartment model comprised an effect compartment linked to the central compartment, sigmoid Emax effect model and parametric method were used to estimate population pharmacodynamic parameters from 26 patients. Serum magnesium concentration was determined by spectrophotometric method ant it was adjusted with basic value determined before dosage. The diastolic blood pressure lowering effect was chosen as index of effect of cardiovascular response. The population pharmacokinetic parameters of magnesium sulfate were: the standard value of K10(h-1), K12(h-1), K21(h-1), and Vc(L.kg-1) were estimated to be 1.62, 20.8, 2.70, and 27.0, respectively. Their interindividual varibilities were estimated to be 25.70%, 14.13%, 24.33%, and 34.04%, respectively. The residual error of concentrations was 15.03%. The population pharmacodynamic parameters of magnesium sulfate were: the standard value of Emax (%), Ce(50) (microgram.ml-1), upsilon, and Keo (h-1) were estimated to be 28.73, 28.39, 4.22, and 0.43. Their interindividual variability were estimated to be 56.32%, 62.24%, 33.47% and 42.76%. The residual error of effect was 28.54%.